Healthcare diagnostics company QuidelOrtho (NASDAQ: QDEL) will be reporting earnings this Wednesday after the bell. Here’s what to expect.
QuidelOrtho beat analysts’ revenue expectations by 5.2% last quarter, reporting revenues of $699.9 million, down 3.7% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting QuidelOrtho’s revenue to be flat year on year at $701.2 million, improving from the 4.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.5% on average.
Looking at QuidelOrtho’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 7.1%, beating analysts’ expectations by 1.7%, and Hologic reported revenues up 2.5%, falling short of estimates by 2.1%. GE HealthCare traded up 4.5% following the results while Hologic’s stock price was unchanged.
Read our full analysis of GE HealthCare’s results here and Hologic’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. QuidelOrtho is down 12.3% during the same time and is heading into earnings with an average analyst price target of $38.33 (compared to the current share price of $29.24).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
